Daijing Yuan

Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials

Zonghai Li, Q. Lu, Y. Zhang, 2020, Clinical Cancer Research.

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

Zonghai Li, Zhi Peng, Xiaotian Zhang, 2022, Nature Medicine.

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Min Yang, Zonghai Li, S. Hao, 2019, Blood.

Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma

Min Yang, Jie Jin, Zonghai Li, 2020 .

CT053, Anti-BCMA CAR T-cell therapy for Relapsed/Refractory Multiple Myeloma: Proof of Concept results from a Phase I Study

Min Yang, Jie Jin, Zonghai Li, 2019, Clinical Lymphoma, Myeloma & Leukemia.

RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial

Z. Liu, T. Liang, W. Fang, 2023, EClinicalMedicine.

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results.

Zhi Peng, J. Gong, Ming Lu, 2024, Nature medicine.